Actively Recruiting
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Led by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Updated on 2025-06-08
138
Participants Needed
21
Research Sites
128 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of TQB3909 tablets in combination with azacitidine in subjects with myeloid malignancies.
CONDITIONS
Official Title
A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntary and signed informed consent with good compliance
- Age 18 years or older at the time of signing informed consent
- Expected survival time greater than 3 months
- Diagnosis of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)
- Normal major organ functions
- Fertile male and female subjects agree to use contraception during the study and for 6 months after study ends
You will not qualify if you...
- Diagnosis of or current other malignancy within 3 years prior to first dose
- Factors affecting oral drug intake or absorption
- Major surgery or significant traumatic injury within 28 days prior to first dose
- History of arterial or venous thrombotic events within 6 months prior to first dose
- History of psychiatric drug abuse that cannot be stopped or psychiatric disorders
- Presence of any severe or uncontrolled disease
- Diagnosis of Acute Promyelocytic Leukemia (APL) or Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)
- Leukemia central nervous system involvement or high suspicion without confirmation
- Extramedullary disease only in AML
- Life-threatening severe leukemia-related complications
- Received live vaccines within 4 weeks prior to first dose or planned during study
- Participation in other clinical trials involving anti-tumor drugs within 4 weeks prior to first dose
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China, 233000
Not Yet Recruiting
2
Beijing Chaoyang Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China, 100020
Not Yet Recruiting
3
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Not Yet Recruiting
4
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China, 102218
Not Yet Recruiting
5
Affiliated Hospital of Chengde Medical University
Chengde, Hebei, China, 67020
Not Yet Recruiting
6
Harbin The First Hospital
Harbin, Heilongjiang, China, 150010
Not Yet Recruiting
7
Henan Provincial People's Hospital
Zhengzhou, Henan, China, 450000
Not Yet Recruiting
8
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071
Not Yet Recruiting
9
Zhuzhou Central Hospita
Zhuzhou, Hunan, China, 412007
Not Yet Recruiting
10
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Not Yet Recruiting
11
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi'an, Shaanxi, China, 710000
Not Yet Recruiting
12
Tai'an Central Hospital (Tai'an Central Hospital affiliated to Qingdao University, Mount Taishan Medical Center)
Taian, Shandong, China, 271099
Not Yet Recruiting
13
Zibo Central Hospital
Zibo, Shandong, China, 255036
Not Yet Recruiting
14
ShangHai Tongren Hospital
Shanghai, Shanghai Municipality, China, 200000
Actively Recruiting
15
Shanghai Yueyang Integrated Traditional Chinese Medicine and Western Medicine Hospital
Shanghai, Shanghai Municipality, China, 200437
Not Yet Recruiting
16
Shanghai Pudong New Area People's Hospital
Shanghai, Shanghai Municipality, China, 201200
Not Yet Recruiting
17
People's hospital of deyang city
Deyang, Sichuan, China, 618099
Not Yet Recruiting
18
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China, 300020
Not Yet Recruiting
19
People's Hospital of Tianjin (City)
Tianjin, Tianjin Municipality, China, 300122
Not Yet Recruiting
20
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China, 830000
Not Yet Recruiting
21
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China, 315010
Not Yet Recruiting
Research Team
J
JianXiang Wang, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here